Obstructive uropathy from locally advanced and metastatic prostate cancer: An old problem with new therapies

Journal of Endourology

Volumn 26, Issue 2, 2012, Pages 102-109

  Friedlander, Justin I ^a   Duty, Brian D ^a   Okeke, Zeph ^a   Smith, Arthur D ^a  

^a The Arthur Smith Institute for Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTIANDROGEN; AQUAPORIN; ATRIAL NATRIURETIC FACTOR; CANCER GROWTH FACTOR; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANTIANDROGEN THERAPY; BLADDER NECK STENOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CYSTOSTOMY; DIURESIS; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; FOLLOW UP; FOREIGN BODY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INFECTION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PERFUSION; LYMPH NODE METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE UROPATHY; ORCHIECTOMY; PERCUTANEOUS NEPHROSTOMY; PERIPHERAL EDEMA; POLYURIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT RESPONSE; ULTRASOUND; UREMIA; URETER CATHETERIZATION; URETER STENT; URINARY TRACT OBSTRUCTION; URINE OSMOLALITY; URINE VOLUME;

HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; URINARY BLADDER NECK OBSTRUCTION; UROLOGIC DISEASES;

EID: 84863068189     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2011.0227     Document Type: Review

References (69)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270: 948-954. (Pubitemid 23244733)
2. Ung JO, Richie JP, Chen MH, et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60:458-463. (Pubitemid 35292173)
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
4. Pais VM, Strandhoy JW, Assimos DG. Pathophysiology of urinary tract obstruction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, vol. 2. 9th ed. Philadelphia: Saunders Elsevier, 2007, pp 1195-1226.
5. Tseng TY, Stoller ML. Obstructive uropathy. Clin Geriatr Med 2009;25:437-443.
6. Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: Optimizing therapeutic and palliative outcomes. J Urol 2008;180:444-450.
7. Klahr S. Obstructive nephropathy. Intern Med 2000;39: 355-361. (Pubitemid 30422100)
8. Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981;304:373-380. (Pubitemid 11167435)
9. Faubert PF, Porush JG. Renal Disease in the Elderly. 2nd ed. New York: Marcel Dekker, 1998, p 441.
10. Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of the prostate: Response to endocrine treatment. Urology 1985;25:354-356. (Pubitemid 16078182)
11. Fleischmann JD, Catalona WJ. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol 1985;134:498-500. (Pubitemid 16236382)
12. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 2002;167:5-9. (Pubitemid 34024483)
13. Mazur AW, Thompson IM. Efficacy and morbidity of "channel" TURP. Urology 1991;38:526-528.
14. Thomas DJ, Balaji VJ, Coptcoat MJ, Abercrombie GF. Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial? J R Soc Med 1992;85:318-319.
15. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 2004;171: 668-671. (Pubitemid 38090453)
16. Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S. Palliative transurethral resection of the prostate: Functional outcome and impact on survival. BJU Int 2007;99: 56-59. (Pubitemid 44915620)
17. Masood S, Djaladat H, Kouriefs C, et al. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 2004;94:1271-1274. (Pubitemid 40052091)
18. Eisenberg ML, Elliott SP, McAninch JW. Preservation of lower urinary tract function in posterior urethral stenosis: Selection of appropriate patients for urethral stents. J Urol 2007;178:2456-2461. (Pubitemid 350052161)
19. Hussain M, Greenwell TJ, Shah J, Mundy A. Long-term results of a self-expanding wallstent in the treatment of urethral stricture. BJU Int 2004;94:1037-1039. (Pubitemid 39577089)
20. Shah DK, Kapoor R, Badlani GH; North American Study Group. Experience with urethral stent explantation. J Urol 2003;169:1398-1400. (Pubitemid 36323795)
21. Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999;54(suppl 6A):8-14.
22. Michigan S, Catalona WJ. Ureteral obstruction from prostatic carcinoma: Response to endocrine and radiation therapy. J Urol 1977;118:733-738. (Pubitemid 8242660)
23. Paul AB, Love C, Chisholm GD. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br J Urol 1994;74:642-645. (Pubitemid 24348634)
24. Sandhu DP, Mayor PE, Sambrook PA, George NJ. Outcome and prognostic factors in patients with advanced prostate cancer and obstructive uropathy. Br J Urol 1992;70:412-416.
25. Honnens de Lichtenberg M, Miskowiak J, Rolff H. Hormonal treatment of obstructed kidneys in patients with prostatic cancer. Br J Urol 1993;71:313-316. (Pubitemid 23102257)
26. Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004;63:1117-1121. (Pubitemid 38746815)
27. Dowling RA, Carrasco CH, Babaian RJ. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer. Urology 1991;37:89-91.
28. Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 1993;24: 118-121. (Pubitemid 23320416)
29. O'Reilly PH. The effect of prostatic obstruction on the upper urinary tract. In: Fitzpatrick JM, Krane RJ, eds. The Prostate. Edinburgh: Churchill Livingstone, 1989, pp 111-118.
30. Saitoh H, Yoshida K, Uchijima Y, et al. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990;65:1843-1846. (Pubitemid 20116661)
31. Megalli MR, Gursel EO, Demirag H, et al. External radiotherapy in ureteral obstruction secondary to locally invasive prostatic cancer. Urology 1974;3:562-564.
32. Shekarriz B, Shekarriz H, Upadhyay J, et al. Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 1999;85:998-1003. (Pubitemid 29077579)
33. Docimo SG, Dewolf WC. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: Experience at 2 institutions. J Urol 1989;142:277-279. (Pubitemid 19197095)
34. Yossepowitch O, Lifshitz DA, Dekel Y, et al. Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 2001;166:1746-1749.
35. Feng MI, Bellman GC, and Shapiro CE. Management of ureteral obstruction secondary to pelvic malignancies. J Endourol 1999;13:521-524. (Pubitemid 29530303)
36. Markowitz DM, Wong KT, Laffey KJ, et al. Maintaining quality of life after palliative diversion for malignant ureteral obstruction. Urol Radiol 1989;11:129-132. (Pubitemid 20066788)
37. Eyre RC, Benotti PN, BotheA, et al.Management of the urinary tract involved by recurrent cancer.Arch Surg 1987;122:493-498. (Pubitemid 17051880)
38. Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 2005;87:21-24. (Pubitemid 40104227)
39. Donat SM, Russo P. Ureteral decompression in advanced nonurologic malignancies. Ann Surg Oncol 1996;3:393-399. (Pubitemid 126729523)
40. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 2005;174:2125-2128. (Pubitemid 41611751)
41. Chung SY, Stein RJ, Landsittel D, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004;172:592-595. (Pubitemid 38900213)
42. Rosevear HM, Kim SP, Wenzler DL, et al. Retrograde ureteral stents for extrinsic ureteral obstruction: Nine years' experience at University of Michigan. Urology 2007;70:846-850. (Pubitemid 350192583)
43. Liu JS, Hrebinko RL. The use of 2 ipsilateral ureteral stents for relief of ureteral obstruction from extrinsic compression. J Urol 1998;159:179-181. (Pubitemid 27525598)
44. Hamm M, Rathert P. [Therapy of extrinsic ureteral obstruction by 2 parallel double-J ureteral stents.] (Ger) Urologe A 1999;38:150-155. (Pubitemid 29155746)
45. Rotariu P, Yohannes P, Alexianu M, et al. Management of malignant extrinsic compression of the ureter by simultaneous placement of two ipsilateral ureteral stents. J Endourol 2001;15:979-583.
46. Hafron J, Ost MC, Tan BJ, et al. Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology 2006; 68:911-915. (Pubitemid 44633397)
47. Liatsikos E, Kallidonis P, Kyriazis I, et al. Ureteral obstruction: Is the full metallic double-pigtail stent the way to go? Eur Urol 2010;57:480-486.
48. Liatsikos EN, Karnabatidis D, Kagadis GC, et al. Metal stents in the urinary tract. EAU-EBU Update Series. 2007;5:77.
49. Liatsikos EN, Karnabatidis D, Katsanos K, et al. Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 2009;182:2613-2617.
50. Christman MS, L'Esperance JO, Choe CH, et al. Analysis of ureteral stent compression force and its role in malignant obstruction. J Urol 2009;181:392-396.
51. Borin JF, Melamud O, Clayman RV. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J Endourol 2006;20:300-304. (Pubitemid 43877475)
52. Wah TM, Irving HC, Cartledge J. Initial experience with the resonance metallic stent for antegrade ureteric stenting. Cardiovasc Intervent Radiol 2007;30:705-710. (Pubitemid 350092255)
53. Kulkarni RP, Bellamy EA. A new thermo-expandable shapememory nickel-titanium alloy stent for the management of ureteric strictures. BJU Int 1999;83:755-759. (Pubitemid 29224391)
54. Kulkarni R, Bellamy E. Nickel-titanium shape memory alloy Memokath 051 ureteral stent for managing long-term ureteral obstruction: 4-year experience. J Urol 2001;166:1750-1754.
55. Agrawal S, Brown CT, Bellamy EA, Kulkarni R. The thermoexpandable metallic ureteric stent: An 11-year follow-up. BJU Int 2009;103:372-376.
56. Lau MW, Temperley DE, Mehta S, et al. Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease. Br J Urol 1995;76:565-569. (Pubitemid 26029690)
57. Schmidbauer J, Kratzik C, Klingler HC, et al. Nephrovesical subcutaneous ureteric bypass: Long-term results in patients with advanced metastatic disease-improvement of renal function and quality of life. Eur Urol 2006;50:1073-1078. (Pubitemid 44486481)
58. Joshi HB, Adams S, Obadeyi OO, Rao PN. Nephrostomy tube or 'JJ' ureteric stent in ureteric obstruction: Assessment of patient perspectives using quality-of-life survey and utility analysis. Eur Urol 2001;39:695-701. (Pubitemid 32679640)
59. Rollig C, Wockel A, Weissbach L. Management of obstructive uropathy patients with advanced prostate cancer-a systematic review. Onkologie 2009;32:680-684.
60. Ku JH, Lee SW, Jeon HG, et al. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: Are there differences? Urology 2004;64:895-899. (Pubitemid 39469501)
61. Slongo LE, de Fraga R, Mitre AI. Endoscopic stented ureterocystostomy. J Endourol 2010; 24:1817-1820.
62. Chiou RK, Chang WY, Horan JJ. Ureteral obstruction associated with prostate cancer: The outcome after percutaneous nephrostomy. J Urol 1990;143:957-959. (Pubitemid 20156103)
63. Bordinazzo R, Benecchi L, Cazzaniga A, et al. Ureteral obstruction associated with prostate cancer: The outcome after ultrasonographic percutaneous nephrostomy. Arch Ital Urol Androl 1994;66(suppl 4):101-106.
64. Harris MR, Speakman MJ. Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit? Prostate Cancer Prostatic Dis 2006;9:42-44 (Pubitemid 43378868)
65. Nariculam J, Murphy DG, Jenner C, et al. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol 2009 82:571-576.
66. Harrington KJ, Pandha HS, Kelly SA, et al. Palliation of obstructive nephropathy due to malignancy. Br J Urol 1995; 76:101-107.
67. Russo P. Urologic emergencies in the cancer patient. Semin Oncol 2000;27:284-298. (Pubitemid 30395162)
68. Russo P. Ureteral obstruction and stents: Still a difficult problem for patients and urologists alike. J Urol 2005;174: 2088. (Pubitemid 41611742)
69. Aravantinos E, Anagnostou T, Karatzas AD, et al. Percutaneous nephrostomy in patients with tumors of advanced stage: Treatment dilemmas and impact on clinical course and quality of life. J Endourol 2007;21:1297-1302. (Pubitemid 350191371)